VYOME HOLDINGS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
VYOME HOLDINGS, INC. (HIND) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$259.36 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-12
- VYOME HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$74.66K.
- VYOME HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$184.70K, a 352.41% decline year-over-year.
- VYOME HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$350.18K, a 396.28% decline year-over-year.
- VYOME HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $617.85K.
- VYOME HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $171.34K.
- VYOME HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$58.86K.
- VYOME HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$3.46M, a 871.65% decline from fiscal 2022.
- VYOME HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $448.00K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$74.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$259.36K 10-Q · filed 2026-08-12 | -$609.54K derived: sum of 3 quarters · filed 2026-08-12 | $8.31K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | -$184.70K 10-Q · filed 2026-05-12 | -$534.88K derived: sum of 2 quarters · filed 2026-05-12 | $82.97K derived: sum of 3 quarters · filed 2026-05-12 | -$86.53K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | -$350.18K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $267.67K derived: sum of 2 quarters · filed 2026-03-18 | $98.17K derived: sum of 3 quarters · filed 2026-08-12 | $171.34K 10-K · filed 2026-03-18 | ||||
| 2025-09-30 | $617.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $448.35K derived: sum of 2 quarters · filed 2026-08-12 | $521.52K 10-Q · filed 2025-11-14 | $639.72K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | -$169.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$96.33K 10-Q · filed 2026-08-12 | -$939.00K 10-Q · filed 2025-08-14 | $21.87K derived: sum of 3 quarters · filed 2026-08-12 | -$52.22K derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-03-31 | $73.17K 10-Q · filed 2026-05-12 | -$27.00K 10-Q · filed 2025-05-20 | $191.37K derived: sum of 2 quarters · filed 2026-05-12 | $117.28K derived: sum of 3 quarters · filed 2026-05-12 | $273.31K derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | $118.19K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $44.11K derived: sum of 2 quarters · filed 2026-03-18 | $200.14K derived: sum of 3 quarters · filed 2026-03-18 | -$58.86K 10-K · filed 2026-03-18 | $820.00K 10-K · filed 2025-04-04 | |||
| 2024-09-30 | -$74.08K derived: 10-Q 9 month − 8-K 6 month · filed 2025-11-14 | $81.95K derived: sum of 2 quarters · filed 2025-11-14 | -$177.05K 10-Q · filed 2025-11-14 | $673.00K 10-Q · filed 2024-11-14 | -$870.05K derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | $156.03K derived: 8-K 6 month − 10-Q 3 month · filed 2025-09-02 | -$102.97K 8-K · filed 2025-09-02 | -$150.00K 10-Q · filed 2024-08-14 | -$795.97K derived: sum of 3 quarters · filed 2025-09-02 | -$726.97K derived: sum of 4 quarters · filed 2025-09-02 | |||
| 2024-03-31 | -$259.00K 10-Q · filed 2025-05-20 | -$952.00K derived: sum of 2 quarters · filed 2025-05-20 | -$883.00K derived: sum of 3 quarters · filed 2025-05-20 | -$4.06M derived: sum of 4 quarters · filed 2025-05-20 | ||||
| 2023-12-31 | -$693.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-04 | -$624.00K derived: sum of 2 quarters · filed 2025-04-04 | -$3.80M derived: sum of 3 quarters · filed 2025-04-04 | -$3.46M 10-K · filed 2025-04-04 | ||||
| 2023-09-30 | $69.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$3.11M derived: sum of 2 quarters · filed 2024-11-14 | -$2.76M 10-Q · filed 2024-11-14 | -$2.27M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | -$3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$2.83M 10-Q · filed 2024-08-14 | -$2.33M derived: sum of 3 quarters · filed 2024-08-14 | -$3.88M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $344.00K 10-Q · filed 2024-05-15 | $843.00K derived: sum of 2 quarters · filed 2024-05-15 | -$708.00K derived: sum of 3 quarters · filed 2024-05-15 | $792.00K derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $499.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$1.05M derived: sum of 2 quarters · filed 2024-04-01 | $448.00K derived: sum of 3 quarters · filed 2024-04-01 | $448.00K 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | -$1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$51.00K derived: sum of 2 quarters · filed 2023-11-09 | -$51.00K 10-Q · filed 2023-11-09 | $129.00K 10-Q · filed 2022-11-14 | $747.00K derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $1.50M 10-K · filed 2023-04-17 | $1.50M 10-Q · filed 2023-08-07 | $1.68M 10-Q · filed 2022-08-19 | $2.30M derived: sum of 3 quarters · filed 2023-05-15 | -$1.39M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2022-03-31 | $240.00K 10-Q · filed 2023-05-15 | $420.00K 10-Q · filed 2022-05-23 | $798.00K derived: sum of 2 quarters · filed 2023-05-15 | -$2.89M derived: sum of 3 quarters · filed 2023-05-15 | -$1.34M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $558.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | -$3.13M derived: sum of 2 quarters · filed 2023-04-17 | -$1.58M derived: sum of 3 quarters · filed 2023-04-17 | -$1.28M 10-K · filed 2023-04-17 | -$1.48M 10-K · filed 2022-04-08 | |||
| 2021-09-30 | -$3.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$2.13M derived: sum of 2 quarters · filed 2022-11-14 | -$1.84M 10-Q · filed 2022-11-14 | -$1.57M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-19 | $1.85M 10-Q · filed 2022-08-19 | $2.12M derived: sum of 3 quarters · filed 2022-08-19 | $1.82M derived: sum of 4 quarters · filed 2022-08-19 | ||||
| 2021-03-31 | $296.00K 10-Q · filed 2022-05-23 | $564.00K derived: sum of 2 quarters · filed 2022-05-23 | $262.00K derived: sum of 3 quarters · filed 2022-05-23 | |||||
| 2020-12-31 | $268.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-08 | -$34.00K derived: sum of 2 quarters · filed 2022-04-08 | -$992.00K 10-K · filed 2022-04-08 | |||||
| 2020-09-30 | -$302.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$1.26M 10-Q · filed 2021-11-12 | ||||||
| 2020-06-30 | -$958.00K 10-Q · filed 2021-08-16 | |||||||
| 2017-09-30 | $476.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $317.00K derived: sum of 2 quarters · filed 2017-11-03 | $534.00K 10-Q · filed 2017-11-03 | $61.00K derived: sum of 4 quarters · filed 2017-11-03 | ||||
| 2017-06-30 | -$159.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $58.00K 10-Q · filed 2017-08-02 | -$415.00K derived: sum of 3 quarters · filed 2017-08-02 | $44.00K derived: sum of 4 quarters · filed 2017-11-03 | ||||
| 2017-03-31 | $217.00K 10-Q · filed 2017-05-10 | -$256.00K derived: sum of 2 quarters · filed 2017-05-10 | $203.00K derived: sum of 3 quarters · filed 2017-11-03 | $89.00K derived: sum of 4 quarters · filed 2017-11-03 | ||||
| 2016-12-31 | -$473.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$14.00K derived: sum of 2 quarters · filed 2017-11-03 | -$128.00K derived: sum of 3 quarters · filed 2017-11-03 | $46.00K 10-K · filed 2017-02-23 | ||||
| 2016-09-30 | $459.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $345.00K derived: sum of 2 quarters · filed 2017-11-03 | $519.00K 10-Q · filed 2017-11-03 | $621.00K derived: sum of 4 quarters · filed 2017-11-03 | ||||
| 2016-06-30 | -$114.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $60.00K 10-Q · filed 2017-08-02 | $162.00K derived: sum of 3 quarters · filed 2017-08-02 | |||||
| 2016-03-31 | $174.00K 10-Q · filed 2017-05-10 | $276.00K derived: sum of 2 quarters · filed 2017-05-10 | ||||||
| 2015-12-31 | $102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $370.00K 10-K · filed 2017-02-23 | ||||||
| 2015-09-30 | $268.00K 10-Q · filed 2016-11-10 | |||||||
| 2014-12-31 | -$33.00K 10-K · filed 2017-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |